Milan, August 14th, 2024 – Numantec, a European leader in the medical devices market, acquires PHS Medical, a German company specialized in the design, production and distribution of single-use port-catheters and respective introducers. Jörg Vesterling, currently PHS’ CEO, will continue to lead PHS while the founder Peter Hankel-Shepherd will continue to support the company as consultant.
Numantec will expand its critical care portfolio and acquire a best-in-class product which has already received MDR and FDA approval. In addition, Numantec will strengthen its presence in the German market, which is one of the key growth areas for the Group. Significant synergies are expected from the Numantec-PHS partnership.
This operation marks another acquisition for the Numantec platform that proves its successful buy and build strategy investing in family-owned companies with proprietary market leading products in specific segments, supported by managers with proven experience and capabilities.
White Bridge Investments, main shareholder of Numantec, will retain the majority of the Group.
Peter Hankel-Shepherd, founder of PHS Medical, claimed: “PHS Medical is a German Company recognized globally by its entrepreneurial excellence thanks to the milestones achieved since its foundation. We believe that Numantec Group today represents the ideal partner to support us in the next growth phase and ensure continuity to what we built so far.”
Jörg Vesterling, CEO of PHS Medical, stated: “The partnership with Numantec will allow us to invest in the development of our firm. I am highly committed to the project and will continue to have an active role as a manager. I have the confidence that this partnership will enable the Group to become a European leader in critical care.”
Gabriele Giovanelli, CEO of Delta Med, added: “PHS Medical is a well-recognized player for the development of port systems, which allowed the company to consolidate its presence in Europe and internationally. We believe that our acquisition strategy to date demonstrated our commitment to offer best-in-class products to our customers, and we will continue along this path.”
In the transaction Numantec was assisted by Colombo & Associati as financial buy side advisor with the partner Nicola Zambianchi and the associate Gianmarco Caruso. White&Case acted as legal advisor, with the partner Alessandro Seganfreddo and the associates Fabian Mayer and Stefania Maracich. Deloitte was responsible for financial and tax due diligence, with a team led by Fabio Grassi with Andrew Eric Griffiths with Giulia Prencipe on the financial aspects and by Yannik Badde with Laura Hörrle and Julia Abzieher on the fiscal aspects. WTW acted as insurance advisor with Gian Paolo Polto and Gabriele Galimberti. Intexo was responsible for the regulatory due diligence with Pietro Caiazza and Vittoria Dardanelli. Proj.Eco Engineering was in charge of the HSE due diligence conducted by Federico Bugliaro Goggia and Alena Ebinghaus (HPC AG).
PHS Medical was supported by DZ BANK as sell side advisor with MD Georgi Bontschev, Vice President David Bechert and Analyst Sebastian Korz, and the legal advisors partner Andreas Lenz, Jörg aus der Fünten, and lawyer Bastian Rieck from Heuking.
